文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

弹性阳离子尼诺霉素载酪氨酸酶质粒(pMEL34)的透皮吸收、基因表达和稳定性增强:在白癜风治疗中的潜在应用。

Enhancement of transdermal absorption, gene expression and stability of tyrosinase plasmid (pMEL34)-loaded elastic cationic niosomes: potential application in vitiligo treatment.

机构信息

Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand.

出版信息

J Pharm Sci. 2010 Aug;99(8):3533-41. doi: 10.1002/jps.22104.


DOI:10.1002/jps.22104
PMID:20213835
Abstract

The pMEL34 was loaded in elastic cationic niosomes (Tween61/Cholesterol/DDAB at 1:1:0.5 molar ratio) by chloroform film method with sonication and rehydrated with 25% ethanol. The amount of pMEL34 was determined by gel electrophoresis and gel documentation. The maximum loading of pMEL34 in elastic cationic niosomes was 150 microg/16 mg of the niosomal compositions. At 8 weeks, the remaining plasmid in the elastic niosomes kept at 4 +/- 2 degrees C, 27 +/- 2 degrees C were 49.75% and 38.57%, respectively, whereas at 45 +/- 2 degrees C, all plasmids were degraded. For transdermal absorption through rat skin investigated by Franz diffusion cells at 6 h, the fluxes of pMEL34 loaded in elastic and nonelastic niosomes in viable epidermis and dermis (VED) were 0.022 +/- 0.00 and 0.017 +/- 0.01 microg/cm(2)/h, respectively, whereas only pMEL34 loaded in elastic cationic noisome was observed in the receiver solution. The pMEL34 loaded in elastic cationic niosomes showed the highest tyrosinase gene expression demonstrating higher tyrosinase activity than the free and the loaded plasmid in nonelastic niosomes of about four times. This study has suggested the potential application of elastic cationic niosomes as an efficient topical delivery for tyrosinase gene in vitiligo therapy.

摘要

pMEL34 通过氯仿膜法加载到弹性阳离子脂双层体(摩尔比为 1:1:0.5 的 Tween61/胆固醇/DDAB)中,并用超声处理和再水化 25%乙醇。pMEL34 的量通过凝胶电泳和凝胶文档确定。弹性阳离子脂双层体中 pMEL34 的最大载药量为 150μg/16mg 脂双层体组合物。在 4°C ± 2°C、27°C ± 2°C 下保存 8 周时,弹性脂双层体中剩余的质粒分别保持 49.75%和 38.57%,而在 45°C ± 2°C 时,所有质粒均降解。通过 Franz 扩散细胞在 6 小时研究经皮透过大鼠皮肤,在活表皮和真皮(VED)中,弹性和非弹性脂双层体中负载的 pMEL34 的通量分别为 0.022 ± 0.00 和 0.017 ± 0.01μg/cm2/h,而只有弹性阳离子脂双层体中负载的 pMEL34 被观察到在接收溶液中。负载在弹性阳离子脂双层体中的 pMEL34 显示出最高的酪氨酸酶基因表达,表现出比非弹性脂双层体中负载和游离质粒高约四倍的酪氨酸酶活性。这项研究表明,弹性阳离子脂双层体作为一种有效的局部传递系统,具有在白癜风治疗中传递酪氨酸酶基因的潜力。

相似文献

[1]
Enhancement of transdermal absorption, gene expression and stability of tyrosinase plasmid (pMEL34)-loaded elastic cationic niosomes: potential application in vitiligo treatment.

J Pharm Sci. 2010-8

[2]
Transdermal enhancement through rat skin of luciferase plasmid DNA loaded in elastic nanovesicles.

J Liposome Res. 2009

[3]
Enhancement of gene expression and melanin production of human tyrosinase gene loaded in elastic cationic niosomes.

J Pharm Pharmacol. 2012-3-22

[4]
Potent enhancement of transdermal absorption and stability of human tyrosinase plasmid (pAH7/Tyr) by Tat peptide and an entrapment in elastic cationic niosomes.

Drug Deliv. 2013

[5]
Anti-inflammatory activity of gel containing novel elastic niosomes entrapped with diclofenac diethylammonium.

Int J Pharm. 2008-8-6

[6]
Potent melanin production enhancement of human tyrosinase gene by Tat and an entrapment in elastic cationic niosomes: potential application in vitiligo gene therapy.

Chem Biol Drug Des. 2012-10-9

[7]
Transdermal absorption enhancement of N-terminal Tat-GFP fusion protein (TG) loaded in novel low-toxic elastic anionic niosomes.

J Pharm Sci. 2010-10-1

[8]
Transdermal absorption enhancement of papain loaded in elastic niosomes incorporated in gel for scar treatment.

Eur J Pharm Sci. 2013-2-14

[9]
Transdermal absorption enhancement through rat skin of gallidermin loaded in niosomes.

Int J Pharm. 2010-4-8

[10]
Transfollicular enhancement of gel containing cationic niosomes loaded with unsaturated fatty acids in rice (Oryza sativa) bran semi-purified fraction.

Eur J Pharm Biopharm. 2012-4-3

引用本文的文献

[1]
Current Advances in Lipid Nanosystems Intended for Topical and Transdermal Drug Delivery Applications.

Pharmaceutics. 2023-2-15

[2]
Lipid-Based Delivery Systems in Development of Genetic and Subunit Vaccines.

Mol Biotechnol. 2023-5

[3]
Nanotechnologies in Delivery of DNA and mRNA Vaccines to the Nasal and Pulmonary Mucosa.

Nanomaterials (Basel). 2022-1-11

[4]
Recent Progress and Future Directions: The Nano-Drug Delivery System for the Treatment of Vitiligo.

Int J Nanomedicine. 2020-5-8

[5]
Advances of Non-Ionic Surfactant Vesicles (Niosomes) and Their Application in Drug Delivery.

Pharmaceutics. 2019-1-29

[6]
Cationic Niosomes as Non-Viral Vehicles for Nucleic Acids: Challenges and Opportunities in Gene Delivery.

Pharmaceutics. 2019-1-22

[7]
Nonionic surfactant vesicles for delivery of RNAi therapeutics.

Nanomedicine (Lond). 2013-11

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索